Semaglutide comes in a tablet now. Here is what that actually changes.

The injection was always the headline and rarely the real obstacle. People manage weekly injections for a dozen chronic conditions without it making the news. What kept this class of drug out of reach was price, supply and a prescribing system that could not decide who was entitled to ask.

A tablet form of semaglutide licensed for weight management arrived this year, and it is a genuine change — just not to the thing most of the coverage said it would change. It is worth being precise about which parts of the problem it solves, because the difference determines whether it is relevant to you.

What it is

Semaglutide is the same molecule whether it is injected weekly or swallowed daily. It is a GLP-1 receptor agonist: it mimics a hormone the gut releases after eating, which slows gastric emptying, acts on appetite signalling in the brain and affects insulin release. An oral version for type 2 diabetes has existed for some years. What is new is an oral version dosed and licensed specifically for weight management.

The practical differences from the injection are a daily rather than weekly schedule, and absorption rules that matter. Oral semaglutide is poorly absorbed by default and the formulation works around that, which is why the instructions about taking it on an empty stomach with a small amount of water, and waiting before eating or taking anything else, are not optional advice. Ignore them and you have taken a much smaller dose than you think.

What it changes

Distribution, mainly. A tablet does not need a cold chain, which makes it far easier to stock, ship and hold — and the shortages that defined the injectable market were largely manufacturing and fill-finish constraints rather than a shortage of the drug itself. A pill also removes the genuine barrier for people with needle phobia, dexterity limits or no fridge they control.

Price has moved too, and moved hard. Direct-pay pricing for the oral version launched well below the four-figure monthly list prices that characterised this market two years ago, with the lower doses cheapest and the price stepping up with the dose. That is the single most consequential change here, and it is also the one most likely to be out of date by the time you read it.

What it does not change

The side effects are the same family, because it is the same drug: nausea, reflux, constipation, and for a minority the gastrointestinal effects that make continuing impossible. Daily dosing gives some people a steadier experience than a weekly peak; it gives others a daily one.

The exclusions are the same. A personal or family history of medullary thyroid carcinoma or MEN2 rules it out. Pancreatitis history, gallbladder disease, severe gastrointestinal conditions and pregnancy all need a real conversation rather than a form. Anyone who has had bariatric surgery, or who takes thyroid hormone or any drug with a narrow therapeutic window, has an absorption question specific to them.

And the fundamental point about this class has not changed: it works while it is taken. Appetite effects recede when the drug stops. Any plan that treats it as a course of treatment with an end date needs to answer what happens at the end, and most do not.

The question of what you are buying from whom

Direct-to-consumer telehealth is now the main route for a large share of prescriptions, and the quality of those services varies more than the marketing suggests. The distinction worth holding is between a service that prescribes a licensed product and one that supplies a compounded preparation. Compounded versions are not the approved drug, are not held to the same manufacturing standards, and have been the subject of repeated regulatory warnings.

If a price looks unlike every other price, that is usually what you are looking at.

What to ask, if you are considering it

Is this the licensed product or a compounded preparation, and can I see the manufacturer’s name. What happens to the price when I move up a dose. Who is reviewing me, how often, and is it the same clinician. What is the plan if I get gastrointestinal effects at week three, and does the service reduce the dose or simply stop supplying. What happens when I stop, and is that conversation part of the service or the end of it.

Take the list. Consultations of this kind are frequently fifteen minutes long, and the questions that get asked are the ones written down.

If your interest in this is not weight

Worth saying plainly: this class is also prescribed for type 2 diabetes and is being studied across a widening set of conditions, and a drug is not a verdict on anybody. The reason to read about it is that it is now common enough that a friend, a parent or a colleague is probably taking it, and the coverage has been unusually poor at separating what is known from what is being sold.

The useful posture is the ordinary one for any medication. Find out what it does, what it costs, what happens when it stops, and who is accountable if it goes wrong. Then decide.